Satellos Bioscience Inc

Satellos Bioscience Inc has a liquidity position characterized by a current ratio of 7.77, indicating strong short-term liquidity, and no long-term debt, which suggests a conservative capital structure. The company holds $9.8 million in cash and equivalents, while total assets amount to $31.9 million, with total liabilities at $4.1 million. The absence of long-term debt and the high current ratio suggest that the company is not reliant on external financing for its operations.

The company's profitability is currently negative, with a return on equity of -89.52% and a return on assets of -78%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. These metrics are below the typical thresholds for a biotechnology firm, which often experiences early-stage losses before commercialization. The operating and net income are both negative, at -$26.46 million and -$24.87 million, respectively.

Satellos Bioscience Inc does not disclose segment or geographic revenue data in the provided financials, so it is not possible to assess revenue concentration or geographic exposure. The company's operations are likely concentrated in its core therapeutic development, but without further data, it is not possible to determine the extent of diversification or geographic reach.

The company is in a growth phase, as indicated by its negative operating and net income, which is common for early-stage biotechnology firms. However, the lack of revenue growth data and the absence of a clear path to profitability make it difficult to assess the trajectory of future growth. The company's capital expenditures are minimal, at -$6,000, suggesting that it is not investing heavily in physical assets at this stage.

The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is not burdened by long-term debt, and its cash reserves are sufficient to cover short-term obligations. However, the negative returns on equity and assets suggest that the company is not generating value for shareholders, which could lead to future dilution if it requires additional capital to fund operations.

There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's financials suggest a stable but unprofitable position, with no immediate signs of distress or transformation.